Reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer
Company provides updates on other initiatives including CNSide™, its proprietary test for neuro-oncology, and COVID-19 testing volume, which has now reached over 450,000 samples
https://finance.yahoo.com/news/medicare-issues-local-coverage-determination-121700546.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.